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Introduction
Appropriate clinical treatment of an individual with multiple
adjacent breast tumors can be difficult to determine. If the
tumors originated from the same clone, then they are likely
to have common genetic changes and behave in a similar
manner. Alternatively, if the tumors are separate primary
lesions, then different genetic pathways might have been
disrupted and the tumors may require separate treatment
strategies [1]. Current methods to detect tumor clonality
include methylation-sensitive restriction enzyme digestions
and detection of X chromosome polymorphisms, neither of
which give an overall genomic assessment of tumors [2].
ER = estrogen receptor; IDC = invasive ductal carcinoma; PR = progesterone receptor; VEGF = vascular endothelial growth factor.
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Abstract
Background: Current methodology often cannot distinguish second primary breast cancers from
multifocal disease, a potentially important distinction for clinical management. In the present study we
evaluated the use of oligonucleotide-based microarray analysis in determining the clonality of tumors
by comparing gene expression profiles.
Method: Total RNA was extracted from two tumors with no apparent physical connection that were
located in the right breast of an 87-year-old woman diagnosed with invasive ductal carcinoma (IDC).
The RNA was hybridized to the Affymetrix Human Genome U95A Gene Chip® (12,500 known human
genes) and analyzed using the Gene Chip Analysis Suite® 3.3 (Affymetrix, Inc, Santa Clara, CA, USA)
and JMPIN® 3.2.6 (SAS Institute, Inc, Cary, NC, USA). Gene expression profiles of tumors from five
additional patients were compared in order to evaluate the heterogeneity in gene expression between
tumors with similar clinical characteristics.
Results: The adjacent breast tumors had a pairwise correlation coefficient of 0.987, and were
essentially indistinguishable by microarray analysis. Analysis of gene expression profiles from different
individuals, however, generated a pairwise correlation coefficient of 0.710.
Conclusion: Transcriptional profiling may be a useful diagnostic tool for determining tumor clonality
and heterogeneity, and may ultimately impact on therapeutic decision making.
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We tested the capabilities of oligonucleotide microarrays
in determining tumor clonality. We obtained samples from
adjacent tumors from a single individual, and compared
the transcriptional profile of each tumor. For comparison,
we determined the gene expression profiles of tumors with
similar clinical characteristics from five different individu-
als. These findings were interpreted in the context of the
observed chip-to-chip variation and with duplicate labeling
of the same RNA source.
Patients and method
Study subjects and selection criteria
Two foci of IDC were removed from the right breast of an
87-year-old woman (tumors 5A and 5B). Neither mam-
mography, intraoperative palpation, nor histologic analysis
revealed a physical connection between these tumors.
Five tumors from separate individuals with the same clini-
cal characteristics were also selected as comparisons
(Table 1, and Supplementary Table 1).
RNA sample preparation
Total RNA was extracted from dissected tumor contain-
ing 90% or greater IDC using TRIzol® (Life Technolo-
gies, Grand Island, NY, USA) followed by RNeasy®
(Qiagen, Valencia, CA, USA). Total RNA (20 µg) was
used to synthesize double-stranded cDNA using Super-
script® Choice System (Life Technologies), and the tem-
plate for an in vitro transcription reaction was used to
synthesize biotin-labeled antisense cRNA (BioArrayTM
High Yield RNA Transcript Labeling Kit; Enzo Diagnos-
tics, Farmingdale, NY, USA). Labeled cRNA was frag-
mented, hybridized, and scanned as described in the
Affymetrix GeneChip® protocol (Affymetrix, Inc).
Affymetrix U95A arrays contain 12,500 known human
genes (see Lipshutz et al [3]).
Data analysis
Expression profiles were analyzed using GeneChip®
Analysis Suite 3.3 (Affymetrix, Inc). Only relative changes
equal to or greater than twofold level of gene expression
were considered. The average difference values obtained
for each tumor were plotted in log scale on scatter graphs
using GeneChip®. The average difference values were
exported into JMPIN® 3.2.6 (SAS Institute, Inc). Then, all
12,500 data points were used to generate a pairwise
(Pearson’s) correlation and, after sorting the average dif-
ference values by magnitude, a ranked (Spearman’s) cor-
relation coefficient for each set of sample comparisons
was calculated [4].
Results
Chip-to-chip variation
In order to measure the variation in gene expression
between individual Affymetrix oligonucleotide arrays, the
labeled cRNA target prepared from tumors 5A and 5B
were each hybridized to two different U95A chips. For
each cRNA sample, approximately 50% of the 12,500
transcripts represented on the chip were considered
‘present’ using Affymetrix algorithms.
The data from the 5A duplicate experiments (5A and
5ADUP) had a pairwise correlation coefficient of 0.995
(Fig. 1). Fifty genes showed a twofold or greater difference
in expression between duplicate data sets. Likewise, the
5B duplicate experiments (5B and 5BDUP) had a pairwise
correlation coefficient of 0.995, with 36 genes showing a
Table 1
Tumor diagnostic characteristics
Tumor*
5A 5B 7 9
Diagnosis IDC IDC IDC IDC
Size (cm) 3.5 3.0 2.2 1.5
Grade
Histologic 2 2 2 2
Nuclear 2 2 2 2
ER status (fmols/mg) 178 (positive) 428 (positive) 250 (positive) 475 (positive)
PR status (fmols/mg) 0 (negative) 4 (negative) 150 (positive) 350 (positive)
S phase 3% 2% Ill-defined G0/G1 peak 4%
Ploidy Diploid Diploid Diploid Diploid
DNA index 1.0 1.0 1.0 1.0
Comments No adjacent DCIS No adjacent DCIS Adjacent DCIS Adjacent DCIS
*Tumors 5A and 5B are separate adjacent tumors from the right breast of an 87-year-old woman; tumors 7 and 9 are from a 36- and a 76-year-old
woman, respectively. DCIS, ductal carcinoma in situ.Breast Cancer Research    Vol 3 No 5 Unger et al
twofold or greater difference in expression (Table 2). None
of the 36 genes that were differentially expressed in the
5B/5BDUP experiment were also differentially expressed in
the 5A/5ADUP experiment, suggesting that these changes
represent random experimental variation.
Variables in sample preparation
In order to measure the variation in gene expression seen
when different cRNA targets are prepared from the same
total RNA source and hybridized to separate U95A chips,
total RNA from tumor 5A was used to prepare cRNA three
weeks after the initial preparation (5AsRNA). Gene expres-
sion patterns from 5A and 5AsRNA had a pairwise correla-
tion coefficient of 0.915, with 165 genes having a twofold
or greater difference in expression (Table 2). Four genes
from the 5A/5ADUP experiment were also differentially
expressed at twofold or greater levels in the comparison of
5A with 5AsRNA. Thus, use of the same RNA source
resulted in the additional perturbation of approximately 100
genes over the observed chip-to-chip variation, again most
likely representing primarily random experimental variation.
Comparison of adjacent tumor gene expression
The gene expression profiles from tumors 5A and 5B had
a pairwise correlation of 0.987, with 149 genes having a
twofold or greater difference in expression (Table 2).
When the expression profiles of cRNA targets from all
duplicate experiments were compared (Table 2), the
observed pairwise correlation ranged from 0.982 to
0.987, with 148–182 genes expressed with twofold or
greater differences. Thus, the number of differentially
expressed genes observed when comparing cRNA
targets prepared from tumors 5A and 5B (149–182
genes) was not greater than that observed with multiple
sample preparations from the same total RNA source
(165 genes). In fact, the pairwise correlation coefficient of
the adjacent tumors (0.987) was higher than those
observed with multiple cRNAs from the same total RNA
source (0.915). Therefore, we conclude that the gene
expression profiles of tumors 5A and 5B are so similar that
they are indistinguishable by the oligonucleotide microar-
ray analysis preformed here. These findings suggest that
tumors 5A and 5B represent multifocal components of the
same tumor, despite a lack of apparent physical contiguity.
Comparison of tumors among different individuals
Tumors 5A and 7 had a pairwise correlation coefficient of
0.787, with 1937 genes having a twofold or greater differ-
ence in expression (Table 2). Likewise, the expression pro-
files of tumors 5A and 9 generated a pairwise correlation
coefficient of 0.745, with twofold or greater differences in
the expression of 1764 genes (Table 2). As expected from
the pairwise correlation data, the expression patterns based
on data from the 5A and 5ADUP experiments have a closer
linear relationship on the scatter plot than that observed
between tumors 5A and 9. Interestingly, tumors 7 and 9 dif-
fered by only 1158 genes with a pairwise correlation coeffi-
cient of 0.874, indicating that these tumors may be more
similar to each other than they are to tumors 5A and 5B.
In order to confirm our results in a larger sample set, we
preformed an analysis on an additional set of invasive
breast tumors from different individuals (tumors 3, 20, and
32) and compared the data with those from tumor 5A, and
Figure 1
Representative log scale scatter plots of average difference values.found similar correlation coefficients to those seen with
tumors 7 and 9 (Supplementary Table 2).
Ranked correlation values of samples
Analysis of the distribution of the average difference values
of each tumor revealed a skewed distribution (data not
shown). Therefore, a nonparametric analysis was used to
examine the complexity of the data. Ranked correlation coef-
ficients were generated to match each of the pairwise cor-
relation coefficients calculated (Table 2). A small drop in
correlation values (by 0.027–0.035) was observed in the
ranked correlations compared with the pairwise correlations
in the duplicate experiments and those that compared
tumors 5A and 5B (Table 2). Conversely, in the pairwise
data sets with lower correlation coefficients (5A/5AsRNA,
5A/7i and 5A/9i), the ranked correlation calculations
increased the correlation values by 0.021–0.098. These
data suggest that a simple pairwise correlation comparison
may not fully represent the relationship between gene
expression profiles. Further analyses of these data distribu-
tions and algorithmic methods for the evaluation of back-
ground and systematic error are currently being conducted.
Expression patterns for selected genes of known
interest in breast cancer
Differences in gene expression for specific genes that are
implicated in breast carcinogenesis were examined. A
breast cancer-associated gene list was derived by query-
ing the Affymetrix EASI® Database U95A, with ‘breast’ as a
search term. A total of 39 genes were identified from this
search, but only 22 of these genes were judged present in
at least one tumor (Table 3). Tumors 5A and 5B only dif-
fered in one breast cancer related gene, the human mam-
maglobin β precursor gene, and showed no differences in
expression for the remaining 22 genes examined, including
hormone response, tumor suppressor and mammary spe-
cific genes. The human mammaglobin protein is overex-
pressed in a variety of breast carcinomas [5,6]. It does not
appear to be consistently found in a specific subclass of
tumors, or is its exact function known. Tumor 5A had signif-
icantly higher levels of expression of the vascular endothe-
lial growth factor (VEGF) gene (2.0-fold), the breast
epithelial antigen (BA46) gene (4.3-fold) and the human
mammaglobin gene (3.6-fold), as compared with tumor 7.
Tumor 5A had a higher level of estrogen receptor (ER)
expression than did tumor 7 (12.7-fold), BARD-1 (2.9-
fold), and thymidylate synthetase (3.0-fold). Tumor 5A had
higher expressions than did tumor 9 of the progesterone
receptor (PR; 2.7-fold), human mammaglobin (36.9-fold),
and the human mammaglobin β precursor (29.1-fold), but
had lower expressions of the androgen receptor (2.5-fold),
VEGF (2.2-fold), BARD-1 (3.5-fold) and thrombospondin-1
(2.2-fold). These findings suggest that, even though these
tumors appear similar in stage, grade and ER status, they
in fact exhibit important differences in gene expression
that may be associated with different clinical behaviors.
Discussion
Microarray technology has tremendous potential in cancer
research and diagnostics. The genetic profiles of tumors
can be assessed and compared in a global manner, thus
improving diagnosis and potentially allowing individualiza-
tion of treatment strategies. Several studies [7–9] have
characterized the gene expression patterns of breast
cancers, but the present study is the first to test the sensi-
tivity and capabilities of oligonucleotide microarray analy-
sis in determining tumor clonality. The expression profiles
of adjacent breast tumors from one individual, and of
tumors with similar diagnostic characteristics (including
Available online http://breast-cancer-research.com/content/3/5/336
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Table 2
Correlation coefficient calculations and fold change differences between tumors
Pairwise correlation  Ranked correlations 
Comparison (all data) (all data) Twofold change* Threefold change* Fourfold change*
5A–5ADUP 0.995 0.962 50 14 3
5B–5BDUP 0.995 0.968 36 10 1
5A–5AsRNA 0.915 0.936 165 34 6
5A–5B 0.987 0.957 149 64 38
5A–5BDUP 0.981 0.951 174 80 38
5ADUP–5B 0.987 0.952 182 88 48
5ADUP–5BDUP 0.982 0.948 182 83 47
5A–7 0.787 0.854 1937 992 598
5A–9 0.745 0.843 1764 887 557
9–7 0.874 0.877 1158 598 339
*Number of genes with twofold, threefold, or fourfold change or greater in expression.grade, stage, and hormone status) from different individu-
als were compared. Additional experiments were pre-
formed to measure chip-to-chip variation and variation in
the probe preparation process. All data sets were sub-
jected to both pairwise and ranked correlation calcula-
tions. These analyses suggest that complex data sets,
such as those derived from microarray experiments, may
require multiple-stage analysis to enhance the ability to
detect changes optimally and to infer biologic significance
from expression profiles.
In the present study, a 0.5% difference was observed in
the expression profiles of duplicate experiments using the
Affymetrix U95A chips. When the total RNA was
hybridized to two different U95A chips, the data were
found to have a 0.915 pairwise correlation. The lower than
expected correlation coefficient, which was related to
sample preparation variation, may be due to a small
amount of RNA degradation. Future experiments will
confirm whether this variation in sample preparation is pre-
dictable as a baseline level. The 5AsRNA expression
profile differed from that of 5A by only 165 genes, which is
within the range observed in tumor comparisons with a
pairwise correlation coefficient of 0.987–0.980. Addition-
ally, when the correlation data were further stratified by
rank, the correlation coefficients of 5A and 5AsRNA more
closely resembled ranked correlations of the 5A and 5B
experiments (Table 2). Regardless, a small amount of chip-
to-chip variation and sample preparation variation is to be
expected when comparing microarray experiments.
The number of genes that were differentially expressed in
tumor 5A as compared with tumor 5B (149–182 genes)
approximates the number of genes that are differentially
expressed as a result of variations in sample preparation
(165 genes). None of the genes that were differentially
expressed between these adjacent tumors had a known
role in breast cancer development. These findings lead us
to conclude that tumors 5A and 5B are essentially indistin-
guishable by microarray analysis, suggesting that they are
likely to be derived from the same clone. Interestingly, little
heterogeneity was detected between tumors 5A and 5B,
despite the fact that both tumors had each grown to a size
of at least 3 cm.
In contrast, the expression profiles of tumors 7 and 9
showed marked differences from that of tumor 5A (correla-
tion coefficients of 0.787 for tumors 5A and 7, and 0.745
for tumors 5A and 9), with the expression of 1937 (tumors
5A and 7) and 1764 (tumors 5A and 9) genes differing by
twofold or greater between tumors. These findings were
confirmed in a larger sample set of three additional invasive
tumors, providing additional support to our findings. It is
interesting to note that pairwise comparisions of tumor 5A
with other invasive tumors had the lowest correlations of all
pairwise comparisons, indicating that tumors 5A and 5B
may be phenotypically distinct from all the other invasive
tumors examined in the present study.
When the gene expression profiles of tumors 5A, 5B, 7,
and 9 were compared, a difference in gene expression for
several genes that are known to be involved in breast
cancer was observed (Table 3). Most interestingly, the
expression profiles of the tumors examined closely reflect
the hormone receptor status, as measured clinically. For
instance, tumor 7 had a lower level of ER transcript than
did tumor 5A, which was paralleled by a decreased ER
content. Tumor 9 had the highest PR gene expression, as
well as the highest PR content. We were not able to
detect a difference in expression of PR between tumors
Breast Cancer Research    Vol 3 No 5 Unger et al
Table 3
Genes of known interest in breast cancer
Tumor
Gene 5A/5B 5A/7 5A/9
ER NC D(12.7) NC
PR NC NC I(2.7)
Androgen receptor NC NC D(2.5)
Epidermal growth factor receptor NC NC NC
ERBB2 NC NC NC
VEGF NC I(2.0) D(2.2)
TP53 NC NC NC
Ataxia telangiectasia (ATM) N CN CN C
FHIT NC NC NC
BRCA2 NC NC NC
RAD50 NC NC NC
BARD-1 NC D(2.9) D(3.5)
Retinoblastoma-1 (RB1) N CN CN C
Amplified in breast cancer (AIB1) N CN CN C
Breast cancer transcription  NC NC NC
factor (ZaBCl)
Thymidylate synthetase NC D(3.0) NC
Multidrug resistance gene (MDR-1) N CN CN C
Thrombospondin-1 NC NC D(2.2)
KI-67 antigen NC NC NC
Breast epithelial antigen (BA46) NC I(4.3) NC
Human mammaglobin NC I(3.6) I(36.9)
Human mammaglobin β precursor I(40.1) NC I(29.1)
In addition to several known cancer genes, this list was derived by
quering the Affymetrix EASI database for genes on the U95A, using
‘breast’ as the search term. D(x), an x-fold decrease in gene expression
in this tumor compared with tumor 5A; I(x), an x-fold increase in gene
expression in this tumor compared to tumor 5A; NC, no change in
gene expression in this tumor compared with tumor 5A.5A and 7, however, despite the fact that tumor 7 was PR
positive (150 fmol/mg) and 5A was PR negative, possibly
representing an expression difference below the sensitivity
of the technology (see below). Lastly, HER2 was measured
as ‘undetectable’ in tumor 9 at diagnosis, but was not mea-
sured in any of the other tumors examined in the present
study. Therefore, the lack of difference in expression of
ERBB2 detected in each of these tumors predicts that
tumors 5A, 5B, and 9 were also Her-2 receptor negative.
Since the initial draft of this report was prepared, it was
learned from Affymetrix that the probe set corresponding
to PR on the version of the U95A chip used in the present
study was not ‘adequately representative’ of the human
mRNA and promoter region DNA of the PR, on the basis
of recent changes to the annotations in the GenBank and
UniGene databases. These findings may present an expla-
nation as to why the gene expression data for the PR in
this study did not correlate with the protein expression
measurements.
Finally, transcripts from several genes that are known to
play a role in breast cancer were not detected in any of
the tumors analyzed, presumably due to low level expres-
sion. These genes include: BRCA1,  EGFR,  VEGF, and
the breast cancer suppressor element, CP1. Thus, there is
an important subset of genes that may not be detected
using this technology because of low transcript levels, or
that may not be regulated at the transcriptional level.
In conclusion, these experiments demonstrate the poten-
tial for oligonucleotide-based microarrays to assess tumor
clonality and tumor heterogeneity. Although it is currently
not cost-effective to array every tumor sample using an
Affymetrix chip, the results of these experiments may lead
to identification of a set of genetic markers that can be
used to generate a smaller diagnostic tumor array for use
in the clinical setting in the near future.
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Supplementary material
Patients and method
Study subjects and selection criteria
An 87-year-old woman underwent an excisional breast
biopsy in 1996 to remove two tumor masses at the
6 o’clock and 9 o’clock positions in her right breast
(tumors 5A and 5B, respectively). Neither mammography,
intraoperative palpation, nor histologic analysis revealed a
physical connection between these tumors. A portion of
the tumor was used for clinical diagnostic purposes and,
with the patient’s consent, the remainder of the tumor was
used for research purposes.
Two tumors from separate consenting individuals were
identified that had the same stage, grade, and ER charac-
teristics as tumors 5A and 5B, based on the pathology
reports (Table 1). The tumors originated from a 36-year-
old woman who underwent a left breast excisional biopsy
in 1997 (tumor 7) and from a 76 year-old woman who
underwent a right excisional breast biopsy in 1998
(tumor 9). The three additional invasive tumors added to
our data analysis originated from excisional breast biop-
sies from a 53 year-old woman (tumor 3), a 44 year-old
woman (tumor 20) and a 54 year-old woman (tumor 32;
Supplementary Table 1). At the time of diagnosis, the
Her-2 receptor was measured as 60% positive for tumor 3
and found to be undetectable in tumor 9. The status of
Her-2 receptor was not measured for any of the other
tumors used in the present study. 
Tumor handling
After the gross pathologic diagnosis was completed, the
remaining portion of each tumor used in the present study
was snap frozen in liquid nitrogen and placed in a freezer
at –80°C until use.
Tumor analysis
In order to confirm the clinical diagnosis and to identify
regions of the tumor specimen that contained 90% or
greater IDC, frozen sections were prepared from each
Available online http://breast-cancer-research.com/content/3/5/336
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surface area was designated the ‘front’ of the tumor,
and the opposing side was designated the ‘back’. A
frozen section was made of the front and back of each
of the tumor, and the sections were stained with hema-
toxylin and eosin to visualize the tumor and to verify that
the cell population content was consistent throughout
the tumor.
Breast Cancer Research    Vol 3 No 5 Unger et al
Supplementary Table 1
Tumor diagnostic characteristics
Tumor
32 0 3 2
Diagnosis IDC IDC IDC
Size (cm) 2.6 1.9 1.5
Grade
Histologic 3 3 3
Nuclear 3 3 3
ER 0 (neg) 0 (neg) 0 (neg)
PR 0 (neg) 0 (neg) 0 (neg)
S phase No data No data 15.3%
Ploidy Aneuploid No data Aneuploid
DNA Index 2.4 No data 1.54
Comments Adjacent DCIS Adjacent DCIS Adjacent DCIS
Tumor 3 is from a 53 year-old woman, and tumors 20 and 32 are from
a 44- and a 54-year-old woman, respectively. DCIS, ductal carcinoma
in situ.
Supplementary Table 2
Gene expression correlations of additional invasive ductal
carcinoma tumors
Pairwise correlation  Ranked correlations 
Comparison (all data) (all data)
5A–20 0.7880 0.8387
5A–32 0.7104 0.8338
5A–3 0.7228 0.8412
20–32 0.8932 0.8902
20–3 0.8420 0.8490
32–3 0.8594 0.8676
9–3 0.8146 0.8488
9–20 0.8339 0.8266
9–32 0.8786 0.8666
7–3 0.8164 0.8554
7–20 0.8629 0.8362
7–32 0.8516 0.8558
Supplementary Figure 1
Hematoxylin and eosin frozen sections taken from tumors. All tumors were diagnosed as IDC, and had similar morphologies and diagnostic
characteristics in the clinical pathology report.Available online http://breast-cancer-research.com/content/3/5/336
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Results
Analysis and confirmation of tumor characteristics
Frozen sections stained with hematoxylin and eosin of
tumors 5A and 5B contained a 90% or greater IDC popu-
lation, as determined by a surgical pathologist (MR), and
thus did not require further dissection. Tumors 3, 7, 9, 20,
and 32 were found to contain small adjacent ductal carci-
noma  in situ components, which were macrodissected
from the IDC portion of the tumors. In order to confirm that
the ductal carcinoma in situ cells were completely removed
from the samples, the dissected tumors were resectioned
and stained. The frozen sections taken of the ‘front’ (see
Supplementary material, Tumour analysis) of tumors 5A,
5B, 7, and 9 may be seen in Supplementary Fig. 1.